Michael A. Mussallem Sells 32,900 Shares of Edwards Lifesciences Corporation (EW) Stock

Edwards Lifesciences Corporation (NYSE:EW) CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction on Monday, October 30th. The shares were sold at an average price of $100.93, for a total transaction of $3,320,597.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Michael A. Mussallem also recently made the following trade(s):

  • On Thursday, September 7th, Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock. The shares were sold at an average price of $112.45, for a total transaction of $3,699,605.00.
  • On Wednesday, August 9th, Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock. The shares were sold at an average price of $115.99, for a total transaction of $3,816,071.00.

Shares of Edwards Lifesciences Corporation (NYSE:EW) traded down 0.28% during trading on Monday, reaching $101.63. The company’s stock had a trading volume of 1,945,085 shares. The stock’s 50 day moving average price is $110.49 and its 200 day moving average price is $112.40. The company has a market cap of $21.46 billion, a PE ratio of 30.82 and a beta of 0.62. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.45.

Edwards Lifesciences Corporation (NYSE:EW) last posted its earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.02). The business had revenue of $821.50 million for the quarter, compared to analyst estimates of $833.85 million. Edwards Lifesciences Corporation had a return on equity of 27.22% and a net margin of 22.47%. The firm’s revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.68 earnings per share. Equities research analysts predict that Edwards Lifesciences Corporation will post $3.75 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Michael A. Mussallem Sells 32,900 Shares of Edwards Lifesciences Corporation (EW) Stock” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.com-unik.info/2017/10/30/michael-a-mussallem-sells-32900-shares-of-edwards-lifesciences-corporation-ew-stock.html.

Several hedge funds have recently bought and sold shares of the stock. ETF Managers Group LLC acquired a new position in Edwards Lifesciences Corporation in the 2nd quarter valued at $112,000. Shine Investment Advisory Services Inc. acquired a new position in Edwards Lifesciences Corporation in the 2nd quarter valued at $126,000. Cornerstone Advisors Inc. grew its holdings in Edwards Lifesciences Corporation by 25.1% in the 2nd quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after buying an additional 219 shares in the last quarter. Alexandria Capital LLC grew its holdings in Edwards Lifesciences Corporation by 1.7% in the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after buying an additional 19 shares in the last quarter. Finally, MPS Loria Financial Planners LLC acquired a new position in Edwards Lifesciences Corporation in the 2nd quarter valued at $140,000. 82.37% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts have issued reports on EW shares. Royal Bank Of Canada reissued a “buy” rating and set a $130.00 price objective on shares of Edwards Lifesciences Corporation in a research report on Friday, July 28th. Stifel Nicolaus reissued a “buy” rating and set a $130.00 price objective (up from $118.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Zacks Investment Research raised shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 target price on the stock in a report on Tuesday, July 18th. SunTrust Banks, Inc. lifted their target price on shares of Edwards Lifesciences Corporation to $14.00 and gave the company a “buy” rating in a report on Monday, July 17th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $135.00 target price (down previously from $155.00) on shares of Edwards Lifesciences Corporation in a report on Wednesday, October 25th. Seven research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $125.17.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

What are top analysts saying about Edwards Lifesciences Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Edwards Lifesciences Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit